The US Food and Drug Administration has issued a finalized guidance on its designation process and criteria for competitive generic therapies. In order to bring clarity to the CGT pathway in the US, the 20-page final guidance “includes several clarifications about the CGT program and its exclusivity provisions.”
After receiving more than 350 CGT requests, the FDA insisted that while the agency may at the request of the...





